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Abstract
Nebivolol, a third generation b-adrenoceptor (b-AR) antagonist (b-blocker), causes vasodilation by inducing nitric oxide (NO)
production. The mechanism via which nebivolol induces NO production remains unknown, resulting in the genesis of much
of the controversy regarding the pharmacological action of nebivolol. Carvedilol is another b-blocker that induces NO
production. A prominent pharmacological mechanism of carvedilol is biased agonism that is independent of Gas and
involves G protein-coupled receptor kinase (GRK)/b-arrestin signaling with downstream activation of the epidermal growth
factor receptor (EGFR) and extracellular signal-regulated kinase (ERK). Due to the pharmacological similarities between
nebivolol and carvedilol, we hypothesized that nebivolol is also a GRK/b-arrestin biased agonist. We tested this hypothesis
utilizing mouse embryonic fibroblasts (MEFs) that solely express b2-ARs, and HL-1 cardiac myocytes that express b1- and b2-
ARs and no detectable b3-ARs. We confirmed previous reports that nebivolol does not significantly alter cAMP levels and
thus is not a classical agonist. Moreover, in both cell types, nebivolol induced rapid internalization of b-ARs indicating that
nebivolol is also not a classical b-blocker. Furthermore, nebivolol treatment resulted in a time-dependent phosphorylation
of ERK that was indistinguishable from carvedilol and similar in duration, but not amplitude, to isoproterenol. Nebivolol-
mediated phosphorylation of ERK was sensitive to propranolol (non-selective b-AR-blocker), AG1478 (EGFR inhibitor),
indicating that the signaling emanates from b-ARs and involves the EGFR. Furthermore, in MEFs, nebivolol-mediated
phosphorylation of ERK was sensitive to pharmacological inhibition of GRK2 as well as siRNA knockdown of b-arrestin 1/2.
Additionally, nebivolol induced redistribution of b-arrestin 2 from a diffuse staining pattern into more intense punctate
spots. We conclude that nebivolol is a b2-AR, and likely b1-AR, GRK/b-arrestin biased agonist, which suggests that some of
the unique clinically beneficial effects of nebivolol may be due to biased agonism at b1- and/or b2-ARs.
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Introduction
Nebivolol is classified as a third generation b-adrenoceptor (b-
AR) antagonist (b-blocker) that has a higher affinity for b1-
adrenoceptors (b1-ARs) compared to b2-ARs and b3-ARs [1,2].
Importantly, nebivolol activates endothelial nitric oxide (NO)
synthase (eNOS) leading to vasorelaxation in vivo and ex vivo [3–5].
Although the mechanism is unknown, a leading theory is that
nebivolol induces vasodilation via b3-ARs [5–8]. However, recent
evidence argues against a mechanism involving human b3-ARs
[9], and nebivolol’s reported affinity for b3-ARs (Ki , 1.5 mM) is
much weaker than for b2-ARs (Ki , 30 nM) and b1-ARs (Ki ,
0.8 nM) [9,10]. Therefore, it seems unlikely that pharmacologi-
cally relevant concentrations of nebivolol would act via b3-ARs,
especially in vivo where 98% of nebivolol is bound to plasma
proteins [11]. Because of the ratios of agonist to antagonist utilized
the most recent reports regarding nebivolol acting through b3-ARs
[5] leaves open the possibility that nebivolol could act, at least in
part, via b1-ARs or b2-ARs. The b3-AR is not the only theorized
target receptor; an alternative theory is that metabolites of
nebivolol induce vasodilation through b2-ARs [12].
Nebivolol abolishes b1- and b2-AR-mediated cAMP generation
in response to classical agonists and does not generate cAMP
through either receptor on its own [9,13,14]. Because of these
antagonistic properties at b1- and b2-ARs, the theories described
previously have grown in acceptance due to viewing nebivolol
solely as a classic antagonist. However, the recently developed
concept of biased agonism indicates that classification based on
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71980
cAMP production alone is not sufficient to dismiss a ligand from
having agonistic properties at b1- and b2-ARs.
Biased agonism is a relatively new term that defines a subset of
functional selectivity [15–17]. G protein-coupled receptors
(GPCRs) signal through at least two mechanisms: the traditional
Ga and Gbc pathways, as well as the more recently appreciated G
protein-coupled receptor kinase (GRK)/b-arrestin pathway. Tra-
ditional agonists signal through both of these mechanisms
simultaneously, and pure antagonists block both pathways
simultaneously; however, biased agonists favor one mechanism
over the other. This bias allows for a ligand to signal differently
than a traditional agonist and, importantly, means that what once
were called ‘‘antagonists’’ (because they inhibit the Ga and Gbc
pathways) may, in fact, activate the GRK/b-arrestin pathway,
which would result in unique properties compared to pure
antagonists.
Thus far, there is only one known clinically utilized GRK/b-
arrestin biased agonist: carvedilol [18,19]. Carvedilol, which is
now available as a generic drug, was originally marketed as a b-
blocker. In 2007, carvedilol was recognized as a biased agonist that
induces b-AR-mediated activation of the GRK/b-arrestin path-
way but not the Gas-coupled/cAMP pathway [19–21]. Further-
more, carvedilol along with the other third generation b-blockers,
such as nebivolol, are unique among b-blockers because they result
in vasodilatation. Like nebivolol, carvedilol-mediated vasodilation
is attributed to nitric oxide (NO) production [22]. Moreover,
carvedilol-mediated NO production and vasodilation may be due,
at least partially, to biased agonism at b-ARs [23].
Given the similarities between carvedilol and nebivolol, it is
possible that they signal through similar mechanisms. Although
studies have examined most b-blockers for biased-agonist activity
[19,20], to date nebivolol has not been examined. Nebivolol is an
intriguing candidate for GRK/b-arrestin biased agonism because
of its similarities with carvedilol and its debated signaling
mechanisms. Since vasodilation can be mediated through an
endothelial cell epidermal growth factor receptor (EGFR)-medi-
ated mechanism [24–26], b-AR-mediated transactivation of the
EGFR through a GRK/b-arrestin biased signaling mechanism
could explain nebivolol-mediated NO production without invok-
ing the need for additional ligand-receptor interactions such as via
b3-ARs. Therefore, we tested the hypothesis that nebivolol is a
GRK/b-arrestin biased agonist.
Assessment of GRK/b-arrestin biased agonism can be accom-
plished through various approaches including phosphorylation of
the receptor, receptor internalization, redistribution of b-arrestins,
and b-arrestin-mediated signaling. To avoid inducing any over-
expression artifacts, we utilized endogenous b-ARs which, due to
poor b-AR specific antibodies [27], limited these studies to: b-AR
internalization and signaling; b-arrestin-mediated signaling and
cellular redistribution; as well as probing for the role of the EGFR
and GRKs. Data generated by these studies collectively indicate
that nebivolol is indeed a GRK/b-arrestin biased agonist.
Methods
Chemicals
Nebivolol was obtained from Forest Laboratories as well as
purchased from Tocris (Bristol, England, UK) and Sigma (St.
Louis, MO). Norepinephrine, isoproterenol, propranolol, alpren-
olol, 3-isobutyl-1-methylxanthine (IBMX), and forskolin were
obtained from Sigma; N-(3-chlorophenyl)-6,7-dimethoxy-4-quina-
zolinanine hydrochloride (AG1478) and methyl 5-[2-(5-nitro-2-
furyl)vinyl]-2-furoate (GRK2 inhibitor) was obtained from EMD
Millipore/Calbiochem (San Diego, CA); and [5,7-3H] (-)-CGP-
12177 (chemical name: 4-[3-[(1,1-dimethylethyl)amino]2-hydro-
xypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydrochloride),
henceforth referred to as 3H-CGP, was obtained from Perkin
Elmer (Waltham, MA). Hoechst 33342 was obtained from Life
Technologies (Carlsbad, CA). All other materials are described
below.
Cell Culture
Mouse embryonic fibroblasts lacking all the Gnas exon 2 derived
products including Gas and XLas (Gnas
E22/E22) have been
described previously [28]. These cells were stably transfected with
a plasmid containing human Gas short driven by an EF-1
promoter and conferring blasticidin resistance. Functional expres-
sion of Gas and b-ARs was confirmed by measuring cAMP
production in the presence and absence of 10 mM isoproterenol
(data not shown). For simplicity, these cells are referred to as MEFs
in this manuscript. The GnasE22/E22 cells and MEFs were grown
in DMEM-F12 supplemented with 10% FBS, 50 units of
penicillin-streptomycin (Life Technologies), and 5 mg/mL blasti-
Table 1. qPCR primers.
Target Primer Sequence (59 to 39)
18 s Forward CGGACAGGATTGACAGATTG
Reverse CAAATCGCTCCACCAACTAA
Probe 6-Fam-CACCACCAC(Zen)CCACGGAATCG-IBFQ
ADRB1 Forward ACTTCGGTAGATGTGCTGTG
Reverse AAACTCTGGTAGCGAAAGGG
Probe 6-Fam-AGGGTCTCA(Zen)ATGCTGGCCGT-IBFQ
ADRB2 Forward CATGGAAGGCTTTGTGAACTG
Reverse GTCTGGTTAGTGTCCTGTCAAG
Probe 6-Fam-AGTCAACGC(Zen)TAAGGCTAGGCACAG-IBFQ
ADRB3 Forward TGATGGCTATGAAGGTGCG
Reverse AAAATCCCCAGAAGTCCTGC
Probe 6-Fam-CGTGAAGGG(Zen)CCGTGAAGATCCA-IBFQ
GRK1 Forward ATTGTGTCTCTGGCCTATGC
Reverse CTGTGTAATAGATGGCCCGTG
Probe 6-Fam-AATGTGGAT(Zen)GAGGATAACCCCGGC-IBFQ
GRK2 Forward TCTTCCAGCCATACATTGAGG
Reverse TCATGGTCAGGTGGATGTTG
Probe 6-FAM-ACAAGTTCA(Zen)CACGGTTCTGCCAGT-IBFQ
GRK3 Forward GATAGACCGAATGACCCTGAC
Reverse ATGTGCTCCTTCAACTCTCG
Probe 6-FAM-CAGCTTCCA(Zen)GATGCCTTCTCCCC-IBFQ
GRK4 Forward ACCTCCAGATATTGTGAAAGAGTG
Reverse GCTGGCATTTGTGTTCTCTTAG
Probe 6-FAM-CGAAGAATG(Zen)TGCTGGGTTTTCTGTCTCC -IBFQ
GRK5 Forward GAGAAGGTTAAGCGGGAAGAG
Reverse TTCGAGTCTTTGGTGAGCAG
Probe 6-FAM-AGAGGCCAA(Zen)GTCCATCTGCAACA-IBFQ
GRK6 Forward GAGCTTCGACTCAGCCTTG
Reverse CATATTCAGACACCCCATCCAG
Probe 6-FAM-CGCCTGTTA(Zen)TTTCGTGAGTTCTGTGC-IBFQ
6-FAM is the fluorescent indicator, Zen is an internally inserted dark quencher,
and Iowa Black FQ (IBFQ) is a second dark quencher.
doi:10.1371/journal.pone.0071980.t001
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cidin from InvivoGen; San Diego, CA (for the MEFs only). These
cells were maintained at 37uC in 5% CO2 plus 95% air humidified
incubator.
Mouse atrial myocytes (HL-1) were a gift from Dr. William
Claycomb (Louisiana State University, New Orleans, LA, USA)
[29]. The myocytes were cultured in complete Claycomb
supplemented with 10% FBS (JRH Biosciences, Lenexa, KS),
penicillin-streptomycin (100 U/ml), norepinephrine (100 U/ml)
and L-glutamine (2 mM) (Life Technologies). The culture flasks
were pre-coated with 12.5 mg/ml fibronectin in 0.02% gelatin
solution (Sigma). The myocytes were also maintained at 37uC in
5% CO2 plus 95% air humidified incubator.
Identification of b-ARs and GRKs
Taq-Man qPCR was utilized to identify the b-AR and GRK
isoforms expressed in MEFs; HL-1 cells and mouse aorta total
RNA (positive control) were also used to identify the b-ARs. The
primers were designed utilizing the online primer designer from
IDT (Coralville, IA) to amplify mouse b1-, b2-, and b3-ARs, and
GRK 2, 3, 4, 5, and 6; additionally a universal 18 s primer was
used as an internal control (Table 1). Qiagen (Valencia, CA)
RNeasy Plus Mini kit with shredder columns were used as directed
to isolate total RNA from confluent plates of cells, and the total
RNA was converted to cDNA using Qiagen’s Omniscript kit with
RNase inhibitor from Promega (Madison, WI). The cDNA,
primers, and TaqMan Universal PCR Master Mix (Life Tech-
nologies) were placed into 0.2 mL AB MicroAmp tubes from Life
Technologies and the samples run on an ABI 7000 with standard
cycling (10 minute 95uC followed by 40 cycles of 15 sec 95uC
Figure 1. qPCR detection of b1-, b2-, and b3-ARs in mouse cells
and tissue. Total RNA was isolated from mouse aorta (A), MEFs, and
HL-1 cells (B) and subjected to 40 rounds of Taq-Man qPCR. Bars with
different Greek letters are statistically different (p,0.05) from each
other according to a one-way ANOVA followed by Kruskal-Wallis
posthoc test. ND indicates that the transcript was not detected; data are
expressed as mean 6 SEM, n = 3 for cells and n= 2 for aorta.
doi:10.1371/journal.pone.0071980.g001
Figure 2. Ligand-mediated b-AR internalization. MEFs (A and B)
and HL-1 cells (C) were stimulated for the indicated amount of time
with isoproterenol (A) or nebivolol (B and C), and surface receptor levels
were determined as described in the methods. Two doses of
isoproterenol (A) and nebivolol (B) were used in the MEFs: 100 nM
(green) and 1 mM (black). Data are expressed as mean 6 SEM (in both
the x and y axis); n = 3 to 4.
doi:10.1371/journal.pone.0071980.g002
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denaturing step and a 1 minute 60uC anneal/extend step). Each
sample was run in triplicate for each of the aforementioned
transcripts. An auto baseline was used to determine the Ct for all
samples, and DCt was determined by subtracting the 18 s from the
paired transcripts. The relative quantification (RQ) method
utilizing 2 (2DDCt) was used to compare the transcripts expression
levels. For b-ARs in MEFs and HL-1 cells, the pooled DCt of b1-
and b2-ARs of mouse aorta was used as the control in the DDCt
method, and for the GRKs in MEFs the b2-AR was used as the
control. Nonparametric statistics were used to analyze the data.
Measurement of cAMP, Purines, and Pyrimidines
MEFs were grown in 12-well plates to near confluence and
serum starved overnight in 750 mL serum free DMEM/F12. All
cells were treated with 500 mM IBMX for 5 minutes, then 1 mM
isoproterenol or 10 mM forskolin was added to the cells. After a
30-minute incubation at 37uC, cells were washed with ice-cold
phosphate buffered saline (PBS) and 500 mL ice-cold 1-propanol
was added to the cells. The cells were incubated for two hours at
4uC, and then the propanol was collected in 1.9 mL tubes and
dried in a rotary evaporator. While the samples were drying, the
fixed cells were stained with 5 mM of the cell permeant Hoechst
33342 dye in a 3% bovine serum albumin from Jackson
ImmunoResearch (West Grove, PA) in PBS for 1 hour. The cells
Figure 3. Nebivolol-mediated changes in nucleoside and related compounds concentrations. MEFs were treated with the indicated
amount of nebivolol, or vehicle control, for 30 minutes in the presence of IBMX. Each compound was measured from a single sample by LC-MS/MS;
the compound examined is listed above each histogram. Bars with different Greek letters are statistically different (p,0.05) from each other
according to a one-way ANOVA followed by Tukey-Kramer post hoc test. Data are expressed as mean 6 SEM; n = 6.
doi:10.1371/journal.pone.0071980.g003
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were then washed 3 times in PBS and each plate was imaged 3
times in a BioTek Synergy HT to account for cell number as
previously described [30]. The dried samples were reconstituted in
200 mL ultrapure water and analyzed on a Thermo Electron TSQ
Quantum-Ultra system with a HESI source utilizing an Agilent
Zorbax eclipse XBD-C-18 column as described previously [31].
b-AR Internalization
A modified protocol from Seibold et al. was utilized [32].
Twelve -well plates were coated with poly-D-lysine (Sigma) and
cells were immediately seeded on the plates. Once confluent the
cells were starved overnight in 750 mL DMEM/F12. For
treatment a 4x solution of agonist (nebivolol or isoproterenol) in
DMEM/F12 was prepared and 250 mL was added to each well.
Two sets of zero time points were used in each experiment. When
the incubation time expired, plates were placed on ice and washed
3 times with 1 mL ice cold DMEM/F12. After washing the cells,
1 mL of DMEM/F12 containing 5 nM of the cell impermeant
3H-CGP [33] and 5 mM Hoechst 33342 was added to all but the
second zero time point. The second zero time point acted as a
control for nonspecific binding; its media contained 5 nM 3H-
CGP, 5 mM Hoechst 33342, plus 1 mM alprenolol. The dishes
were then incubated for 1 hour at 4uC after which the solution was
removed and the samples washed twice with ice cold DMEM/F12
and once with ice cold PBS. The PBS was removed and the plate
imaged to determine the intensity of the Hoechst stain in a BioTek
FLx800 fluorometer 3 times. The cells were removed from the
plate by adding 200 mL trypsin/EDTA (Life Technologies) for at
least 30 minutes at 37uC. All of the solution was removed from the
wells and placed into scintillation vials; 5 mL scintillation fluid was
added to the vials and the 3H-CGP counted on a Beckman LS
6000IC scintillation counter. Cell surface receptors were deter-
mined by the ratio of 3H-CGP/Hoechst; Hoechst 33342 staining
intensity is directly related to cell number [30]. The nonspecific
binding was then subtracted from each individual point and data
were expressed as percent of total surface receptors at time zero.
Data were fit to and analyzed with a one-phase decay model in
GraphPad Prism 5 for Windows.
Western Blots
MEFs and HL-1 cells were grown in 60 mm and 100 mm tissue
culture plates, respectively, serum starved overnight (at least 12
hours) then either not pretreated (for nebivolol signaling experi-
ments) or pretreated for 30 minutes with DMSO (vehicle), 1 mM
AG1478, or 30 mM propranolol. Following treatment, cells were
stimulated with an agonist (nebivolol, carvedilol, or isoproterenol)
for up to 30 minutes, then lysed in lysis buffer (1% Triton X-100,
100 mM NaCl, 20 mM Tris, pH 7.5, 2 mM EDTA, 10 mM
MgCl2, 10 mM NaF, 40 mM b-glycerol phosphate, supplemented
with 1 mM PMSF and 2 mM Na3VO4). The samples were
clarified by centrifuging the lysate at 14,000 rpm for 5 minutes at
4uC and removing the supernatant, then Laemmli sample buffer
was added and the samples were boiled and stored at -20uC before
analysis. The samples were separated on a 9% SDS-PAGE gel and
transferred to nitrocellulose obtained from BioRad (Hercules, CA).
ERK activation was measured via running duplicate gels and
blotting with phospho-specific ERK1/2 (E10) antibodies on one
blot and for total ERK1/2 on the second blot. When examining b-
arrestins an additional gel (triplicate) was run and probed with b-
arrestin 1/2 (D24H9) antibody. To examine GRK expression level
Figure 4. Nebivolol time-dependently and Gas-independently signals to ERK. MEFs were treated with 100 nM of isoproterenol, 1 mM of
nebivolol, or 100 nM of carvedilol for the indicated time points (A); representative blots are shown above the graph. Data are compared by one-way
ANOVA with Kruskal-Wallis Multiple comparison post-hoc test; two asterisk (**) indicates significantly different than control by Bonferroni method
(more stringent) and one asterisk (*) indicates significantly different by the regular test (less stringent). GnasE22/E22 cells were treated with 100 nM of
isoproterenol and 1 mM of nebivolol for the indicated time points (B); representative blots are shown above the graph. These data were compared as
in panel A. The data obtained from the MEFs and GnasE22/E22 cells were compared directly for nebivolol- (C) and isoproterenol-mediated (D)
phosphorylation of ERK. Data are compared by two-way ANOVA with Sidak’s multiple comparisons post-hoc test; the cross ({) indicates that the MEFs
and GnasE22/E22 cells are significantly different from each other. HL-1 cardiomyocytes were treated with 10 mM of nebivolol for the indicated time
points (E); representative blots are shown above the graph. These data were compared as in panel A. All data are expressed as mean 6 SEM; n = 3 to
6.
doi:10.1371/journal.pone.0071980.g004
Figure 5. Nebivolol signals to ERK through b-ARs and the EGFR.
Cells were pretreated with inhibitors for 30 minutes then stimulated
with 10 mM of nebivolol for 7 minutes. Representative blots from MEFs
(A) are presented above the histogram of the data; D =DMSO, A = 1 mM
of AG1748, and P= 30 mM of propranolol. Open bars are controls, and
black bars are nebivolol treated. (B) Identical confirmatory experiments
were conducted in two sets of HL-1 cells. All data were analyzed via a
two-way ANOVA with Tukey-Kramer post hoc analysis, and significance
is denoted by Greek letters. Any data set with a different Greek letter is
statistically different p,0.05. Data are expressed as mean 6 SEM;
n = 4 for MEFs and n= 2 for HL-1 cells.
doi:10.1371/journal.pone.0071980.g005
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the blots were probed with GRK specific antibodies and
normalized to actin. The ERK and b-arrestin antibodies were
from Cell Signaling Technology (Beverly, MA) and the GRK and
actin antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA); the HRP-conjugated secondary antibodies were
obtained from Jackson ImmunoResearch Laboratories, and ECL
was obtained from Pierce (Rockford, IL). The images were
captured and analyzed using a BioRad ChemiDoc XRS system
running quantity one software or a Kodak 1500 system running
Carestream software.
siRNA Knockdown of b-arrestin 1 and 2
Pooled mouse specific siRNA towards b-arrestin 1 (barr1) (sc-
29742) and b-arrestin 2 (barr2) (sc-29743), as well as non-targeting
siRNA-A and fluorescein conjugated control siRNA-A were
obtained from Santa Cruz Biotechnology. The siRNA was diluted
per the manufacturer’s specifications and transfected into the
MEFs utilizing Life Technologies siPORT Amine following the
manufacturer’s instructions except that the cells were allowed to
remain attached to the tissue culture dish. The final concentration
of siRNA transfected into the cells was 50 nM. The transfection
media was left in the cells for two days, then the cells were serum
starved overnight and the procedures under the western blot
section were followed. Transfection efficiency was examined
utilizing the fluorescein conjugated control siRNA-A with a Zeiss
Axiovert 40 fluorescent microscope.
b-arrestin Redistribution
MEFs were prepared for imaging as described previously [34].
Nebivolol (10 mM) was used to stimulate the cells for up to 30
minutes. The primary antibodies barr1 (sc-9182 K-16) and barr2
(sc-13140 H-9) from Santa Cruz Biotechnology were used at 1:200
dilution, the fluorophore labeled secondary antibodies Alexa Fluor
555 Donkey Anti-Goat IgG for barr1 as well as Alexa Fluor 647
Figure 6. GRK expression and role in nebivolol-mediated phosphorylation of ERK. qPCR was used to identify the GRKs present in MEFs (A);
data are expressed as mean 6 SEM, n= 3. Western blots for GRK2, 4, 5, and 6 as well as actin, as a control, from GNASE22/E22 cells, MEFs, and
heterologously expressed GRKs from 293T cells (positive controls) were used to confirm the qPCR data via identifying the protein expression of GRKs
(B). MEFs were pretreated with the GRK inhibitor for 30 minutes then stimulated with 10 mM of nebivolol for 7 minutes (C). Representative blots are
presented above the histogram of the data. Open bars are controls, and black bars are nebivolol treated. Data are expressed as mean6 SEM; n = 4. All
data were analyzed by a one-way ANOVA with Tukey-Kramer post hoc analysis, and significance is denoted by Greek letters. Any data set with a
different Greek letter is statistically different p,0.05.
doi:10.1371/journal.pone.0071980.g006
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Donkey Anti-Mouse IgG for barr2 were used at a 1:250 dilution
when conducting dual staining. barr1 did not generate a strong
signal over background; therefore, the replicates utilized single
staining with the barr2 antibody and utilized 1:250 Alexa Fluor
488 Donkey Anti-Mouse IgG as a secondary antibody. 5 mM
Hoechst 33342 was used to identify the nuclei. The images were
acquired with a Leica SPE confocal microscope utilizing a HCX
PL APO CS 100x 1.4 NA oil objective and 405, 561, and 635 nm
laser lines. All images were acquired at a resolution of 102461024
with identical settings for each image, and each image is an
average of 3 repetitive scans. For analysis of barr2 redistribution
and accumulation in vesicles, ImageJ was utilized to identify the
punctate staining that represents aggregated barr2. Aggregation
creates a greater intensity of the pixels than diffuse staining;
therefore, the aggregates were identified and counted utilizing a
filter to only display pixels that are greater than or equal to 64
(25% of full intensity), 96 (38% of full intensity), 128 (50% of full
intensity), and 192 (75% of full intensity) intensity units. The
identified punctate staining was then manually counted for each
cell, and the following formula was used to integrate the number of
vesicles with the threshold where the vesicles were visible: (# only
seen at 64 intensity units * 64/255)+(# only seen at 96 intensity
units * 96/255)+(# only seen at 128 intensity units * 128/255)+(#
only seen at 192 intensity units * 192/255). The original data was
obtained from 4 to 5 individual images of a cell; to increase the
sample size for analysis by nonparametric statistics, resampling
was used to create 8 separate sets of data. The means from each set
were used in the analysis. Following analysis the image intensity
was enhanced in Photpshop utilizing a sigmoidal green curve to
improve visibility of the images; each image was enhanced equally.
Statistics and Data Analysis
All graphs were generated with GraphPad Prism 6, and the
Pearson’s correlation and two-way ANOVAs were also performed
in GraphPad. One-way ANOVAs with Tukey-Kramer post hoc
tests for normal data sets and Kruskal-Wallis posthoc test for non-
normal data sets were conducted with NCSS 2007; the post-hoc
tests are indicated in each figure legend. The data in the figures
are expressed as mean 6 SEM; textual data utilizes confidence
intervals and standard deviation as detailed in the text.
Results and Discussion
As there is still debate regarding the role of the b3-AR in
nebivolol-mediated signaling, the expression of b-ARs in MEFs
and HL-1 cardiac myocyte cells were examined via qPCR. Since
both of these cells originate from mice, and mouse aorta expresses
all three subtypes of b-ARs [35,36], mouse aorta was used as a
Figure 7. b-arrestins are required for nebivolol-mediated
phosphorylation of ERK. siRNA directed towards b-arrestin 1 and 2
were transfected into MEFs; 72 hours later the cells were stimulated
with 10 mM of nebivolol for 7 minutes. A representative blot for b-
arrestins and total ERK is depicted in panel A above the histogram of
the data: even numbers were treated with nebivolol; 1 & 2– non
targeting siRNA, 3 & 4– mock transfection, 5 & 6– barr1 siRNA, 7 & 8–
barr2 siRNA, 9 & 10– barr1+ barr2 siRNA. The efficacy of the siRNA was
analyzed via a one-way ANOVA with Tukey-Kramer post hoc analysis;
statistical difference is denoted by Greek letters; any data set with a
different Greek letter is statistically different p,0.05. Data are expressed
as mean 6 SEM; n = 16. The ERK phosphorylation data (B), collected
only from samples where b-arrestins were knocked down by 25% or
more, are expressed as the percent change induced by nebivolol. These
data were analyzed via a one-way ANOVA with a nonparametric
Kruskal-Wallis post hoc test. Statistical difference (p,0.05) is denoted
by Greek letters; any data set with a different Greek letter is statistically
different. Data are expressed as mean 6 SEM; n = 5 to 9. Due to the
poor knockdown of b-arrestins, a scatter plot of nebivolol-induced
phosphorylation of ERK and b-arrestin level was generated (C) and a
Pearson’s correlation was run to determine the relationship between b-
arrestin level and nebivolol-mediated phosphorylation of ERK (n = 38);
the dotted lines represent the 95% confidence interval of the line.
doi:10.1371/journal.pone.0071980.g007
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positive control. The primer pairs were able to amplify all b-ARs
subtypes in the mouse aorta (Fig. 1A) and no statistical difference
was observed between the receptors although the b3-AR tended to
have lower expression. b1-ARs were found only in the HL-1 cells,
and b2-ARs were found in both MEFs and HL-1 cells (Fig. 1B). b3-
AR message was below detection levels in both MEFs and HL-1
cells even after 40 cycles of PCR under the conditions used in this
study. Expectedly, the cardiac myocyte HL-1 cells contained
significantly more b1-AR message than b2-AR message; in HL-1
cells the b1-AR crossed the threshold ,8 cycles before the b2-AR,
which corresponds to approximately 256-fold greater expression of
b1-AR mRNA compared to b2-AR mRNA. Importantly, these
data indicate that none of the following results are likely to be
attributed to the b3-AR, and the MEFs allow for examining
predominately, if not only, b2-ARs.
As the GRK/b-arrestin pathway is classically involved in
receptor internalization and ligands that activate the GRK/b-
arrestin pathway induce receptor internalization, we examined
whether nebivolol stimulation resulted in internalization of b-ARs
as a first test of biased agonism. Before examining the effect of
nebivolol on b-AR internalization, we validated the internalization
assay and determined the rates of isoproterenol-mediated b-AR
internalization utilizing 3H-CGP. CGP is a cell impermeant b1-
and b2-AR antagonist and a b3-AR agonist [33,37]; however, it
has much lower affinity for b3-ARs compared to the b1- and b2-
ARs [38] and there are no detectable b3-ARs in the cells studied.
Therefore, the observed effects cannot be attributed to b3-ARs.
MEFs treated with 100 nM and 1 mM isoproterenol displayed a
time and concentration dependent internalization of the b2-AR
(Fig. 2A); since MEFs only express b2-ARs, we attribute the
observed effects in MEFs to b2-ARs. There was at least a 2.5
minute time delay in the 100 nM isoproterenol-mediated b2-AR
internalization; however, once internalization was initiated it
progressed with a tK of 6.260 min (95% confidence interval (CI):
3.516 to 28.510 min). The delay in internalization and the rate
were concentration dependent; 1 mM isoproterenol induced
internalization without any delay and resulted in a statistically
shorter tK of 1.315 min (95% CI: 1.046 to 1.769 min; p,0.05 vs.
100 nM) representing a greater rate of internalization. Similarly,
10 mM of isoproterenol (not shown) had no delay and an even
more rapid rate of internalization with a tK of 0.6928 min (95%
CI: 0.5347 to 0.9836 min, p,0.05, vs. 1 mM). In all cases the
plateau of the model, which represents the equilibrium between
receptor internalization and recycling to the surface, was
approximately 40% of the total surface receptor. Following
nebivolol treatment, similar results were observed. 100 nM
nebivolol had no effect for at least 2.5 minutes, but then the b2-
AR internalized with a tK of 2.301 min (95% CI: 1.481 to
5.162 min). 1 mM nebivolol induced internalization of the b2-AR
with a tK of 1.302 min (95% CI: 0.8900 to 2.422 min) (Fig. 2B).
Although the rates were not different in a statistically significant
manner, the plateaus were statistically different; 66.46% (95% CI:
60.48 to 72.44%) of receptors remained on the surface versus
39.81% (95% CI: 34.59 to 45.04%) in the 100 nM and 1 mM
nebivolol treated samples, respectively (p,0.05). We also exam-
ined the effect of nebivolol on the b1- and b2-ARs in HL-1 cells
(Fig. 2C); 1 mM nebivolol induced internalization of the b-ARs
with a tK of 0.6555 min (95% CI: 0.4365 to 1.316 min) and a
plateau of 40% of the surface receptors. These data demonstrate
that nebivolol induces internalization of b-ARs in a manner that is
similar to that of a full agonist. Thus, nebivolol is not a pure
antagonist because pure antagonists do not induce receptor
internalization. Therefore, either nebivolol is a partial agonist at
the b-ARs that leads to robust internalization, a GRK/b-arrestin
biased agonist at the b1- and b2-ARs, or acts as an agonist at an
unknown receptor that causes heterologous desensitization of the
b-ARs.
To begin to determine which of the previous possible
explanations describes the observed effects of nebivolol we tested
the hypothesis that nebivolol is a partial agonist. If nebivolol is a
partial agonist then 39,59-cAMP (cAMP from adenylyl cyclase)
should increase in a statistically significant concentration-depen-
dent manner. MEFs treated with 100 nM nebivolol for 30
minutes, a concentration that causes internalization, failed to alter
39,59-cAMP levels (Fig. 3A); control and 100 nM nebivolol-
stimulated levels of 39,59-cAMP were (mean 6 standard deviation)
14.4864.39 and 14.1261.52 (n= 6) pg/100,000 cells, respective-
ly. This result decouples the internalization, which is similar to the
full agonist isoproterenol, from cAMP production suggesting that
nebivolol is not a partial agonist. On the other hand, 2 and 20 mM
nebivolol slightly, and dose-dependently, increased cAMP levels
but not to a level that was statistically different from baseline; 2
and 20 mM nebivolol resulted in (mean 6 standard deviation)
17.0065.31 and 21.3366.65 (n= 6), pg/100,000 cells, respective-
ly. This corresponds to a 1.17 and 1.47 fold increase in 39,59-
cAMP at 2 and 20 mM nebivolol, respectively. In a separate
experiment, MEFs were treated with 10 mM of isoproterenol,
which resulted in a greater than 30-fold increase in cAMP levels
(data not shown), confirming that we can detect an agonist’s effects
on 39,59-cAMP, and that the nebivolol-mediated increase in
cAMP is exceedingly low. Previous studies indicate that nebivolol
has no effect on cAMP [13,14], including studies using individually
expressed b-ARs [9]; the discrepancy between those studies and
our data are likely due to two factors: 1) LC-MS-MS detection of
39,59-cAMP is the most sensitive technique, and 2) the previous
study utilizing cloned b2-ARs halted at 1 mM nebivolol and did
record a nonsignificant increase in cAMP levels at 1 mM.
Collectively the data regarding nebivolol-mediated cAMP pro-
duction indicates that at concentrations attained in the serum
upon clinically used doses of nebivolol, there is no effect on cAMP
levels, but at higher concentrations (1 mM and greater) there
appears to be marginal cAMP accumulation suggesting that
nebivolol may be a weak partial agonist. However, this statistically,
and likely biologically, insignificant increase in 3959-cAMP does
not correlate with, or explain, the internalization data that mirrors
a full agonist. This finding suggests that the other mechanisms to
explain nebivolol’s effects, biased agonism or a second receptor,
are more plausible.
The LC-MS/MS procedure for examining cAMP allows for the
quantification of a host of nucleosides and nucleotides, as well as
their precursors and metabolites in the same samples [31]. As
shown in the rest of Figure 3, nebivolol increased the amount of
Figure 8. Subcellular distribution of b-arrestin 2 following stimulation with nebivolol. MEFs were treated with vehicle (A and B) or 10 mM
of nebivolol for 1 (C), 2, (D), 3.5 (E), 5 (F), 7 (G), 10 (H), 15 (I), 20 (J), or 30 (K) minutes, and stained as described in the methods. Only Alexa 647
secondary antibody and Hoechst 33342 were used in panel A; addition of primary barr2 antibody (H-9), shown in green, occurred in B through K. All
settings remained identical for each image; the scale bar in panel A represents 10 mm. Panel L represents vesicular barr2 in green on the left axis
(n = 8) and 10 mM nebivolol-mediated phosphorylation of ERK in black on the right axis (n = 3 to 7). For both data sets a Kruskal-Wallis Multiple
comparison test was run and two asterisk (**) indicates significantly different from control by the Bonferroni method (more stringent) and one
asterisk (*) indicates significantly different by the regular test (less stringent).
doi:10.1371/journal.pone.0071980.g008
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inosine, guanosine, uridine, cytidine, 59-AMP, and xanthine in a
concentration dependent manner. Nebivolol either had no effect
on, or did not statistically increase, the levels of adenosine, 29-
AMP, 39-AMP, hypoxanthine, thymidine, and uric acid (only
adenosine (Fig. 3H) is shown); additionally, 29,39-cAMP was not
detected (Fig. 3I). 29,39-cAMP is generally formed from the
breakdown of the poly-A tails on mRNA and is found in
abundance in apoptotic cells [39]; therefore, nebivolol did not
trigger the degradation of mRNA and is likely not toxic in MEFs.
The constellation of nucleosides that were increased suggests that
there is increased translation and transcription, which fits with
previous studies indicating that nebivolol increases dimethylargi-
nine dimethylaminohydrolase transcript and protein levels [40]
and that it alters microRNA expression [41]. Adenosine did not
increase, which appears to contradict the translation and
transcription hypothesis, yet this may be due to a portion of the
increased inosine originating from adenosine degradation. Taken
together, the data support previous findings that nebivolol
increases translation and transcription. Importantly, all of the
statistically different concentration-response changes occurred
when there was an absence of a statistically different effect on
the cAMP concentration-response. This confirms that nebivolol is
not a pure antagonist and demonstrates that nebivolol alters other
molecules more potently and efficaciously than 39,59-cAMP,
indicating that it is not a classical partial agonist, as it does not
affect all downstream targets equally, which is the definition of
biased agonism.
A common signaling pathway initiated by GRK/b-arrestin
biased agonists is the phosphorylation of ERK through transacti-
vation of the EGFR, and EGFR-mediated signaling as well as
ERK-mediated signaling is known to increase transcription and
translation. To investigate if nebivolol signals in this manner, its
time-, receptor-, and GRK-dependent signaling to ERK was
examined. First the time course of 1mM of nebivolol-mediated
phosphorylation of ERK was compared to 100 nM of isoproter-
enol and 100 nM of carvedilol (Fig. 4A). Isoproterenol stimulation
resulted in a robust phosphorylation of ERK that peaked at 10
minutes and returned to baseline at 30 minutes; whereas nebivolol
and carvedilol stimulation increased ERK phosphorylation only
half maximally, compared to isoproterenol, and displayed a
shallow peak at 15 minutes. The time profile of nebivolol and
carvedilol were nearly identical suggesting that they signal through
a common mechanism. It should be noted that nebivolol has an
approximately 30-fold lower affinity than carvedilol at the b2-AR
[10,42], which is why we used greater amounts of nebivolol.
Additionally, 10 mM of nebivolol induced a similar time-depen-
dent phosphorylation of ERK as 1 mM of nebivolol (shown with
confocal images), except that it appeared to elicit a biphasic
response. To further determine if these effects are due to partial
agonism at the b2-AR, the parental Gnas
E22/E22 cells, which lack
all Gas transcripts [28], were treated with 100 nM of isoproterenol
and 1 mM of nebivolol (Fig. 4B). Both isoproterenol and nebivolol
stimulation resulted in an approximate 2-fold increase in ERK
phosphorylation for the duration of the experiment, which was
statistically different from control at multiple points for both
agonists. The effects of the two drugs were indistinguishable in the
GnasE22/E22 cells suggesting that nebivolol and isoproterenol act
similarly when the b2-AR cannot signal through Gas, and that
nebivolol signals to ERK independently of Gas. Nebivolol
treatment of MEFs and GnasE22/E22 cells yielded results that
were not different from each other in a statistically significant
manner, but the results did not appear identical (Fig. 4C). The two
curves match perfectly for the first 5 minutes, and converge again
at 20 minutes. This effect may have been due to differences over
time in the cells after stable transfection with Gas or due to the
slight accumulation of cAMP; however, the data clearly demon-
strated that Gas is not absolutely required for nebivolol-mediated
signaling. Supporting this conclusion, isoproterenol treatment of
MEFs and GnasE22/E22 cells were significantly different from each
other at 10 and 15 minutes of stimulation (Fig. 4D). To confirm
that nebivolol stimulation leads to ERK phosphorylation in a
different cell line, HL-1 cells were stimulated with 10 mM of
nebivolol (Fig. 4E). HL-1 cells responded more rapidly and more
variably than the MEFs with a peak at 5 minutes. These
experiments indicate that nebivolol can signal to ERK and that
this signaling does not require Gas, thus providing more evidence
that nebivolol is not a classical antagonist and that nebivolol fits
the profile of a biased agonist. However, these experiments leave
open the possibility that nebivolol is acting as an agonist at a novel
receptor that causes these effects.
To examine directly the role of b-ARs, as well as EGFRs, in
nebivolol-mediated phosphorylation of ERK, MEFs and HL-1
cells were pretreated for 30 minutes with vehicle, 30 mM of
propranolol, or 1 mM of AG1748 prior to stimulation with 10 mM
of nebivolol for 7 minutes. Nebivolol-mediated phosphorylation of
ERK in MEFs was fully inhibited by both the b-blocker
propranolol and the EGFR kinase inhibitor AG1748 (Fig. 5A).
This confirms that nebivolol-mediated phosphorylation of ERK
emanates from b2-ARs and EGFRs in MEFs, similar to what is
known for carvedilol [20]. However, this experiment does not
distinguish if b2-AR activation precedes EGFR activation or vice
versa. Yet, it is unlikely that nebivolol is an EGFR agonist. To
confirm that these effects are not exclusive to MEFs, a pair of
confirmatory experiments was conducted in HL-1 cells (Fig. 5B).
The effects in HL-1 cells are indistinguishable from the MEFs,
confirming that nebivolol signals through the b-ARs and EGFR
and that this signaling is not cell type dependent. Additionally,
identical experiments were conducted in MEFs with 1 mM of
nebivolol and similar results were obtained (data not shown).
These data confirm that nebivolol signals through b1- and b2-ARs,
as well as EGFRs, to ERK. Collectively, these data strongly
suggest that nebivolol is a GRK/b-arrestin biased agonist of b2-
and b1-ARs and, like carvedilol, is inducing transactivation of the
EGFR; however, these data do not directly examine GRKs or b-
arrestin.
To examine the role of GRKs in nebivolol-mediated phos-
phorylation of ERK we first identified the isoforms of GRKs
expressed in MEFs. qPCR indicates that GRK2 is expressed at
levels significantly greater than any other GRK (Fig. 6A). As
expected, the negative control, the retinal specific GRK1, is not
expressed in MEFs isolated from the torso and appendages of the
embryo. Surprisingly, GRK3 message is also not expressed. To
confirm that the mRNA levels relate to protein we utilized specific
GRK antibodies to detect GRKs 2 through 6 in GNASE22/E22
cells and MEFs (Fig. 6B). Cloned GRKs expressed in 293T cells
were used as positive controls, and in this process it was found that
the GRK3 antibody also detected GRK2 and therefore GRK3
was not included in the analysis. There appears to be much greater
protein levels of GRK2 than the GRK4 family; additionally, the
bands for GRK5 are higher than expected as shown by stably
expressing full length, sequence verified, GRK5 in MEFs. These
data support the conclusion from the qPCR data that GRK2 is the
most abundant GRK. Fortunately, there is a small molecule
inhibitor of GRK2 available [43], allowing for the examination of
the role of GRK2 in nebivolol-mediated phosphorylation of ERK.
As shown in Figure 6C, 100 mM of the GRK2 inhibitor reduced
nebivolol-mediated phosphorylation of ERK. Although nebivolol
significantly increases phosphorylated ERK levels, due to the
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inhibitor alone slightly increasing phosphorylated ERK levels the
samples treated with the GRK2 inhibitor were not statistically
distinct from nebivolol treatment or the control. However,
nebivolol failed to increase phosphorylated ERK levels in the
presence of GRK2 inhibitor, supporting the conclusion that
nebivolol-mediated phosphorylation of ERK requires GRK kinase
activity.
To determine if there is a role for b-arrestins, siRNA directed
against b-arrestins was utilized to knockdown b-arrestin-1 (barr1)
and b-arrestin-2 (barr2). If nebivolol-mediated phosphorylation of
ERK is initiated through b2-ARs and involves b-arrestins, then
decreases in barr1 and/or barr2 should reduce nebivolol-mediated
phosphorylation of ERK. To determine if this is the case, siRNA
was used to decrease barr1 and barr2 separately; however, the
siRNA was not specific and minimally reduced the amount of both
arrestins (Fig. 7A). Only pooling the barr1 and barr2 siRNA
resulted in significant knockdown of both b-arrestins. Therefore,
the signaling analysis was conducted by pooling the barr1 and
barr2 data and using a cutoff of 25% knockdown for inclusion in
the signaling studies (Fig. 7B). These experiments were conducted
identically to the inhibitor studies described in Figure 5 and 6, and
the data are expressed as the mean change in nebivolol-induced
ERK phosphorylation. In control (no siRNA) and MEFs
transfected with non-targeting siRNA, nebivolol stimulation led
to increased levels of phosphorylated ERK; however, when b-
arrestins were knocked down by 25% or greater, nebivolol, on
average, failed to increase phosphorylation of ERK. This finding is
consistent with the conclusion that nebivolol is a biased agonist.
Since only a fraction of the samples fall within the 25% or more
reduction in b-arrestins level, we plotted the level of phosphor-
ylated ERK against the levels of b-arrestin (Fig. 7C). As expected
for a GRK/b-arrestin biased agonist, there is a statistically positive
Pearson’s correlation (r = 0.3926, P= 0.0148) between the level of
b-arrestin and the ability for nebivolol to stimulate ERK.
To confirm that b-arrestins are involved in nebivolol-mediated
effects, confocal imaging was used to examine the redistribution of
b-arrestins following 10 mM of nebivolol treatment. b-arrestin
redistribution occurs when arrestins are activated and can be
visualized by the accumulation of b-arrestin at the plasma
membrane and/or through accumulation of vesicular structures
represented by a punctate staining. Therefore, time dependent b-
arrestin redistribution can be used as an assay to identify GRK/b-
arrestin biased agonists [44]. Two independent experiments were
conducted to examine the cellular distribution of b-arrestins: dual
staining for barr1 and barr2, and staining for just barr2 shown in
Figure 8. This sequence demonstrated that the antibody used for
barr2 produced a much greater signal than barr1; the barr1 signal
was too faint to reliably measure over background. As the levels of
barr1 and barr2 are relatively equal in MEFs as shown in
Figure 7A, we attributed the observed difference in staining to the
quality of the b-arrestin specific antibodies and therefore only
analyzed barr2 distribution. Very little signal was present with
only the secondary antibody (Fig. 8A), whereas diffuse cytoplasmic
staining of barr2 was observed in control cells (Fig. 8B). Treatment
with 10 mM of nebivolol for 1 minute had a marginal effect on
barr2 distribution, yet some membrane localization was detectable
(Fig. 8C, white arrow represents membrane localized barr2). Two
to 20 minutes of stimulation with nebivolol resulted in a clear
redistribution of b-arrestins into punctate structures (Fig. 8D–J);
whereas, 30 minutes of stimulation with nebivolol resulted in a
staining pattern similar to control and 1 minute stimulation
(Fig. 8K). Quantification of vesicle number and intensity shows
that nebivolol-mediated redistribution of b-arrestins follows a
biphasic curve with a peak at 3.5 and 15 minutes and then
approaches the baseline (Fig. 8L). This suggests that the cellular
distribution of barr2 is returning to the basal state 30 minutes after
stimulation. Additionally, the biphasic barr2 redistribution pattern
is similar to, but precedes, 10 mM nebivolol-mediated phosphor-
ylation of ERK (Fig. 8L). In accordance with the siRNA depletion
of b-arrestins (Fig. 7), the barr2 peaks preceding the phosphor-
ylation of ERK peaks suggest that nebivolol-mediated barr2
activation precedes ERK phosphorylation. These data indicate
that nebivolol treatment induces redistribution of barr2 further
supporting the conclusion that nebivolol is a biased agonist.
The mechanism(s) via which nebivolol induces signal transduc-
tion is of interest due to the ability of nebivolol, a highly specific
b1-AR antagonist [2], to stimulate NO production [3,4]. This
fundamental contradiction has been baffling and is at least one of
the reasons that numerous theories regarding the mechanism of
action of nebivolol have been proposed. Herein, we present data
that indicates nebivolol is a b2-AR, and likely b1-AR, GRK/b-
arrestin biased agonist. This explains how a b-blocker that is
highly specific for the b1-AR results in activating signaling
pathways without invoking the need for a second receptor.
However, it remains an open question if this explains the unique
in vivo effects attributed to nebivolol [41,45]. Further studies will
have to be conducted to answer this question fully; however, these
data present a plausible explanation for nebivolol-mediated
signaling, specifically in the endothelium. Most transactivation
studies indicate that the ligand activating the EGFR is a heparin-
bound EGF-like growth factor (HB-EGF) [46,47]. Furthermore,
HB-EGF stimulates endothelial cell eNOS expression and activity
[24] and induces arteriolar vasodilation in a NO-dependent
manner [26]. Therefore, it is possible that the biased agonist effect
of nebivolol is responsible for generation of NO through
transactivation of the EGFR within endothelial cells.
The narrow theory regarding signaling presented above should
not be thought of as the only feature of nebivolol. Recent studies
utilizing a GRK/b-arrestin biased agonist towards the angiotensin
type 1 receptor indicate that GRK/b-arrestin biased agonism
leads to phosphorylation of several proteins [48] and that some of
the phosphorylation sites are unique to the GRK/b-arrestin biased
agonist [49]. Therefore, it is likely that nebivolol shares some
signaling pathways with specific b1- and/or b2-AR agonists, but
nebivolol likely induces unique signaling pathways although these
pathways still emanate from the b1- and/or b2-AR. This may have
a clinical role; multiple studies indicate that b-arrestins and b-
arrestin-mediated signaling are important in cardiac physiology
[50], and GRK/b-arrestin biased agonists promote myocyte
survival [23,51]. Therefore, it is likely that the biased agonist
property of nebivolol plays a crucial role in its clinical profile.
Conclusion
Nebivolol is a GRK/b-arrestin biased agonist at the b2-AR as
demonstrated by the data obtained from the MEFs. It is also likely
a GRK/b-arrestin biased agonist at the b1-AR as demonstrated by
the data obtained from HL-1 cells. These conclusions are
supported by the following constellation of results. After 40 cycles
of qPCR the b3-AR was readily observed in the control but not the
MEFs or HL-1 cells. Nebivolol induces b-AR internalization;
phosphorylation of ERK through b-ARs, GRK, b-arrestin, as well
as the EGFR; redistribution of b-arrestin-2; and it increased
nucleoside cellular concentrations without significantly altering
cAMP. These effects may explain the recently described physio-
logical differences between treatment with nebivolol and classical
b-AR antagonists such as atenolol and metoprolol [41,45].
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